1
|
Fallacara A, Marchetti F, Pozzoli M, Citernesi UR, Manfredini S, Vertuani AS. Formulation and Characterization of Native and Crosslinked Hyaluronic Acid Microspheres for Dermal Delivery of Sodium Ascorbyl Phosphate: A Comparative Study. Pharmaceutics 2018; 10:E254. [PMID: 30513791 PMCID: PMC6321467 DOI: 10.3390/pharmaceutics10040254] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Revised: 11/20/2018] [Accepted: 11/26/2018] [Indexed: 01/14/2023] Open
Abstract
The present work evaluates for the first time the use of urea-crosslinked hyaluronic acid (HA-CL), a novel derivative of native hyaluronic acid (HA), to produce microspheres (MS) by emulsification-solvent evaporation, for dermal delivery of sodium ascorbyl phosphate (SAP). As the term of comparison, HA MS were prepared. A pre-formulation study-investigation of the effects of polymers solutions properties (pH, viscosity) and working conditions-led to the - production of optimized HA-CL MS and HA-CL-SAP MS with: almost unimodal size distributions; mean diameter of 13.0 ± 0.7 and 9.9 ± 0.8 µm, respectively; spherical shape and rough surface; high yield, similar to HA MS and HA⁻SAP MS (≈ 85%). SAP was more efficiently encapsulated into HA-CL MS (78.8 ± 2.6%) compared to HA MS (69.7 ± 4.6%). Physical state, thermal properties, relative moisture stability of HA-CL MS and HA-CL⁻SAP MS were comparable to those of HA MS and HA⁻SAP MS. However, HA-CL⁻SAP MS exhibited an extended drug release compared to HA⁻SAP MS, despite the same kinetic mechanism-contemporaneous drug diffusion and polymer swelling/dissolution. Therefore, HA-CL formulation showed a greater potential as microcarrier (for encapsulation efficiency and release kinetic), that could be improved, in future, using suitable excipients.
Collapse
Affiliation(s)
- Arianna Fallacara
- Department of Life Sciences and Biotechnology, Master Course in Cosmetic Science and Technology (COSMAST), University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara (FE), Italy.
- Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Faculty of Medicine and Health, The University of Sydney, 431 Glebe Point Road, Glebe, NSW 2037, Australia.
- I.R.A. Istituto Ricerche Applicate s.r.l., Via Del Lavoro 4a/6, 20865 Usmate-Velate (MB), Italy.
| | - Filippo Marchetti
- Department of Life Sciences and Biotechnology, Master Course in Cosmetic Science and Technology (COSMAST), University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara (FE), Italy.
| | - Michele Pozzoli
- Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Faculty of Medicine and Health, The University of Sydney, 431 Glebe Point Road, Glebe, NSW 2037, Australia.
| | - Ugo Raffaello Citernesi
- I.R.A. Istituto Ricerche Applicate s.r.l., Via Del Lavoro 4a/6, 20865 Usmate-Velate (MB), Italy.
| | - Stefano Manfredini
- Department of Life Sciences and Biotechnology, Master Course in Cosmetic Science and Technology (COSMAST), University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara (FE), Italy.
- Ambrosialab Srl, Via Mortara 171, 44121 Ferrara (FE), Italy.
| | - And Silvia Vertuani
- Department of Life Sciences and Biotechnology, Master Course in Cosmetic Science and Technology (COSMAST), University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara (FE), Italy.
- Ambrosialab Srl, Via Mortara 171, 44121 Ferrara (FE), Italy.
| |
Collapse
|